In vivo evaluation of a MPC polymer coated continuous flow left ventricular assist system

Shin'ichiro Kihara; Kenji Yamazaki; Kenneth N. Litwak; Philip Litwak; Marina V. Kameneva; Hiroyuki Ushiyama; Toshimasa Tokuno; David C. Borzelleca; Mitsuo Umezu; Jun Tomioka; Osamu Tagusari; Takehide Akimoto; Hitoshi Koyanagi; Hiromi Kurosawa; Robert L. Kormos; Bartley P. Griffith

doi:10.1046/j.1525-1594.2003.t01-2-06993.x

In vivo evaluation of a MPC polymer coated continuous flow left ventricular assist system

Shin'ichiro Kihara^*, Kenji Yamazaki, Kenneth N. Litwak, Philip Litwak, Marina V. Kameneva, Hiroyuki Ushiyama, Toshimasa Tokuno, David C. Borzelleca, Mitsuo Umezu, Jun Tomioka, Osamu Tagusari, Takehide Akimoto, Hitoshi Koyanagi, Hiromi Kurosawa, Robert L. Kormos, Bartley P. Griffith

^*Corresponding author for this work

School of Fundamental Science and Engineering

Research output: Contribution to journal › Article › peer-review

75 Citations (Scopus)

Abstract

The aim of this study was the evaluation of the thrombogenicity and the biocompatibility of the SunMedical EVAHEART left ventricular assist system (LVAS) coated with 2-methacryloyloxyethyl phosphorylcholine (MPC) polymer compared to a diamond-like carbon (DLC) coating. Four calves were implanted with the MPC polymer-coated LVAS. Eight calves were implanted with DLC coated LVAS. The thrombogenicity and biocompatibility of the pumps were evaluated. At explant, 60.0 ± 37.2% (5-85%) of the pump surface area was still coated with MPC polymer after the duration of 45.0 ± 32.0 days. In 1 out of 4 MPC and 2 out of 8 DLC coated pumps, there was a very small amount of thrombus around the seal ring; otherwise the blood contacting surfaces were free of thrombus. Major organs were normal except for a few lesions in kidneys from both groups. The MPC polymer coated EVAHEART LVAS seems to have low thrombogenicity and high biocompatibility similar to the DLC coated system. The current study demonstrated that the MPC polymer coating shows great promise for being used as an antithrombogenic substrate for the LVAS due to its ease of application, significant cost benefit, and reduction in anticoagulation therapy in acute postoperative period.

Original language	English
Pages (from-to)	188-192
Number of pages	5
Journal	Artificial Organs
Volume	27
Issue number	2
DOIs	https://doi.org/10.1046/j.1525-1594.2003.t01-2-06993.x
Publication status	Published - 2003 Feb 1

Keywords

2-methacryloyloxyethyl phosphorylcholine
Biocompatibility
Diamond-like carbon
Left ventricular assist device
Rotary blood pump
Thrombogenicity

ASJC Scopus subject areas

Bioengineering
Medicine (miscellaneous)
Biomaterials
Biomedical Engineering

Access to Document

10.1046/j.1525-1594.2003.t01-2-06993.x

Cite this

Kihara, S., Yamazaki, K., Litwak, K. N., Litwak, P., Kameneva, M. V., Ushiyama, H., Tokuno, T., Borzelleca, D. C., Umezu, M., Tomioka, J., Tagusari, O., Akimoto, T., Koyanagi, H., Kurosawa, H., Kormos, R. L., & Griffith, B. P. (2003). In vivo evaluation of a MPC polymer coated continuous flow left ventricular assist system. Artificial Organs, 27(2), 188-192. https://doi.org/10.1046/j.1525-1594.2003.t01-2-06993.x

Kihara, S, Yamazaki, K, Litwak, KN, Litwak, P, Kameneva, MV, Ushiyama, H, Tokuno, T, Borzelleca, DC, Umezu, M, Tomioka, J, Tagusari, O, Akimoto, T, Koyanagi, H, Kurosawa, H, Kormos, RL & Griffith, BP 2003, 'In vivo evaluation of a MPC polymer coated continuous flow left ventricular assist system', Artificial Organs, vol. 27, no. 2, pp. 188-192. https://doi.org/10.1046/j.1525-1594.2003.t01-2-06993.x

@article{ef84edd7d1b74039b47e6365d0780d14,

title = "In vivo evaluation of a MPC polymer coated continuous flow left ventricular assist system",

abstract = "The aim of this study was the evaluation of the thrombogenicity and the biocompatibility of the SunMedical EVAHEART left ventricular assist system (LVAS) coated with 2-methacryloyloxyethyl phosphorylcholine (MPC) polymer compared to a diamond-like carbon (DLC) coating. Four calves were implanted with the MPC polymer-coated LVAS. Eight calves were implanted with DLC coated LVAS. The thrombogenicity and biocompatibility of the pumps were evaluated. At explant, 60.0 ± 37.2% (5-85%) of the pump surface area was still coated with MPC polymer after the duration of 45.0 ± 32.0 days. In 1 out of 4 MPC and 2 out of 8 DLC coated pumps, there was a very small amount of thrombus around the seal ring; otherwise the blood contacting surfaces were free of thrombus. Major organs were normal except for a few lesions in kidneys from both groups. The MPC polymer coated EVAHEART LVAS seems to have low thrombogenicity and high biocompatibility similar to the DLC coated system. The current study demonstrated that the MPC polymer coating shows great promise for being used as an antithrombogenic substrate for the LVAS due to its ease of application, significant cost benefit, and reduction in anticoagulation therapy in acute postoperative period.",

keywords = "2-methacryloyloxyethyl phosphorylcholine, Biocompatibility, Diamond-like carbon, Left ventricular assist device, Rotary blood pump, Thrombogenicity",

author = "Shin'ichiro Kihara and Kenji Yamazaki and Litwak, {Kenneth N.} and Philip Litwak and Kameneva, {Marina V.} and Hiroyuki Ushiyama and Toshimasa Tokuno and Borzelleca, {David C.} and Mitsuo Umezu and Jun Tomioka and Osamu Tagusari and Takehide Akimoto and Hitoshi Koyanagi and Hiromi Kurosawa and Kormos, {Robert L.} and Griffith, {Bartley P.}",

year = "2003",

month = feb,

day = "1",

doi = "10.1046/j.1525-1594.2003.t01-2-06993.x",

language = "English",

volume = "27",

pages = "188--192",

journal = "Artificial Organs",

issn = "0160-564X",

publisher = "Wiley-Blackwell",

number = "2",

}

TY - JOUR

T1 - In vivo evaluation of a MPC polymer coated continuous flow left ventricular assist system

AU - Kihara, Shin'ichiro

AU - Yamazaki, Kenji

AU - Litwak, Kenneth N.

AU - Litwak, Philip

AU - Kameneva, Marina V.

AU - Ushiyama, Hiroyuki

AU - Tokuno, Toshimasa

AU - Borzelleca, David C.

AU - Umezu, Mitsuo

AU - Tomioka, Jun

AU - Tagusari, Osamu

AU - Akimoto, Takehide

AU - Koyanagi, Hitoshi

AU - Kurosawa, Hiromi

AU - Kormos, Robert L.

AU - Griffith, Bartley P.

PY - 2003/2/1

Y1 - 2003/2/1

N2 - The aim of this study was the evaluation of the thrombogenicity and the biocompatibility of the SunMedical EVAHEART left ventricular assist system (LVAS) coated with 2-methacryloyloxyethyl phosphorylcholine (MPC) polymer compared to a diamond-like carbon (DLC) coating. Four calves were implanted with the MPC polymer-coated LVAS. Eight calves were implanted with DLC coated LVAS. The thrombogenicity and biocompatibility of the pumps were evaluated. At explant, 60.0 ± 37.2% (5-85%) of the pump surface area was still coated with MPC polymer after the duration of 45.0 ± 32.0 days. In 1 out of 4 MPC and 2 out of 8 DLC coated pumps, there was a very small amount of thrombus around the seal ring; otherwise the blood contacting surfaces were free of thrombus. Major organs were normal except for a few lesions in kidneys from both groups. The MPC polymer coated EVAHEART LVAS seems to have low thrombogenicity and high biocompatibility similar to the DLC coated system. The current study demonstrated that the MPC polymer coating shows great promise for being used as an antithrombogenic substrate for the LVAS due to its ease of application, significant cost benefit, and reduction in anticoagulation therapy in acute postoperative period.

AB - The aim of this study was the evaluation of the thrombogenicity and the biocompatibility of the SunMedical EVAHEART left ventricular assist system (LVAS) coated with 2-methacryloyloxyethyl phosphorylcholine (MPC) polymer compared to a diamond-like carbon (DLC) coating. Four calves were implanted with the MPC polymer-coated LVAS. Eight calves were implanted with DLC coated LVAS. The thrombogenicity and biocompatibility of the pumps were evaluated. At explant, 60.0 ± 37.2% (5-85%) of the pump surface area was still coated with MPC polymer after the duration of 45.0 ± 32.0 days. In 1 out of 4 MPC and 2 out of 8 DLC coated pumps, there was a very small amount of thrombus around the seal ring; otherwise the blood contacting surfaces were free of thrombus. Major organs were normal except for a few lesions in kidneys from both groups. The MPC polymer coated EVAHEART LVAS seems to have low thrombogenicity and high biocompatibility similar to the DLC coated system. The current study demonstrated that the MPC polymer coating shows great promise for being used as an antithrombogenic substrate for the LVAS due to its ease of application, significant cost benefit, and reduction in anticoagulation therapy in acute postoperative period.

KW - 2-methacryloyloxyethyl phosphorylcholine

KW - Biocompatibility

KW - Diamond-like carbon

KW - Left ventricular assist device

KW - Rotary blood pump

KW - Thrombogenicity

UR - http://www.scopus.com/inward/record.url?scp=0344838635&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0344838635&partnerID=8YFLogxK

U2 - 10.1046/j.1525-1594.2003.t01-2-06993.x

DO - 10.1046/j.1525-1594.2003.t01-2-06993.x

M3 - Article

C2 - 12580778

AN - SCOPUS:0344838635

SN - 0160-564X

VL - 27

SP - 188

EP - 192

JO - Artificial Organs

JF - Artificial Organs

IS - 2

ER -

In vivo evaluation of a MPC polymer coated continuous flow left ventricular assist system

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this